NVO Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 136.88 |
| 52 Week High | DKK 148.15 |
| 52 Week Low | DKK 86.96 |
| Beta | 0.13 |
| 11 Month Change | 2.70% |
| 3 Month Change | 0.62% |
| 1 Year Change | 47.70% |
| 33 Year Change | 164.32% |
| 5 Year Change | 420.16% |
| Change since IPO | 75,420.42% |
Recent News & Updates
Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
Aug 18Novo Nordisk: Growth Only Limited By Manufacturing Capacity
Aug 07Novo Nordisk: Better Buying Opportunities Ahead
Jul 26Recent updates
Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
Aug 18Novo Nordisk: Growth Only Limited By Manufacturing Capacity
Aug 07Novo Nordisk: Better Buying Opportunities Ahead
Jul 26Novo Nordisk: Buy On Dips
Jul 04Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
Jun 26Novo Nordisk: Leading The Fight Against Diabetes And Obesity
Jun 18Novo Nordisk: Considerable Growth Beyond Ozempic
May 27The FTC Cracks Down On Novo Nordisk's Ozempic
May 03Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Apr 26Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
Mar 07Novo Nordisk, A Very Healthy Pharma Stalwart
Feb 28Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
Feb 23Novo Nordisk: Irrational Exuberance Isn't Worth The Risk
Feb 16Novo Nordisk: Outlook For Weight Loss Drugs In 2024
Jan 22Taking Novo Nordisk To The Next Level
Jan 15Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
Jan 02Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
Dec 12Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation
Nov 24Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
Oct 24Novo Nordisk: Catching The Falling Knife Now Could Really Hurt
Sep 22Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
Aug 30Novo Nordisk: Denmark's Coca-Cola
Jul 25The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
Jul 11Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care
Jun 23Shareholder Returns
| NVO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.5% | 1.7% | 0.4% |
| 1Y | 47.7% | 18.8% | 25.3% |
Return vs Industry: NVO exceeded the US Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: NVO exceeded the US Market which returned 25.3% over the past year.
Price Volatility
| NVO volatility | |
|---|---|
| NVO Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NVO has not had significant price volatility in the past 3 months.
Volatility Over Time: NVO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 69,260 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NVO fundamental statistics | |
|---|---|
| Market cap | US$608.27b |
| Earnings (TTM) | US$13.38b |
| Revenue (TTM) | US$38.41b |
45.4x
P/E Ratio15.8x
P/S RatioIs NVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVO income statement (TTM) | |
|---|---|
| Revenue | DKK 258.00b |
| Cost of Revenue | DKK 39.92b |
| Gross Profit | DKK 218.09b |
| Other Expenses | DKK 128.19b |
| Earnings | DKK 89.90b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
| Earnings per share (EPS) | 20.28 |
| Gross Margin | 84.53% |
| Net Profit Margin | 34.84% |
| Debt/Equity Ratio | 50.7% |
How did NVO perform over the long term?
See historical performance and comparison